AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9820373 — intervention group
Group type: COMPARATOR
Intervention: Patients with ulcerative colitis (no folate supplementation)
Number of subjects: 36
Study 9820373 — intervention group
Group type: COMPARATOR
Intervention: Patients with Crohn's colitis (no folate supplementation)
Number of subjects: 36
Study 9820373 — intervention group
Group type: COMPARATOR
Intervention: Folate status (measured in serum, whole blood, and colonic mucosa)
Number of subjects: 36
Study 8164029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg i.v. plus ondansetron 8 mg i.v. prechemotherapy plus ondansetron 8 mg orally every 12 hours postchemotherapy for nine doses
Number of subjects: 302
Study 8164029 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone 10 mg i.v. plus ondansetron 16 mg i.v. prechemotherapy plus placebo orally postchemotherapy
Number of subjects: 302
Study 8164029 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 10 mg i.v. plus ondansetron 8 mg prechemotherapy plus ondansetron 8 mg orally postchemotherapy for one dose followed by placebo orally every 12 hours for eight more doses
Number of subjects: 302
Study 8164029 — intervention group
Group type: COMPARATOR
Intervention: Placebo orally postchemotherapy
Number of subjects: 302
Study 2845011 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternating chemotherapy (cyclophosphamide, Adriamycin, vincristine alternating with etoposide and cisplatin)
Number of subjects: 0
Study 31994254 — intervention group
Group type: EXPERIMENTAL
Intervention: Juul (59 mg nicotine/ml)
Number of subjects: 20
Study 31994254 — intervention group
Group type: COMPARATOR
Intervention: Cigarettes
Number of subjects: 20
Study 31994254 — intervention group
Group type: COMPARATOR
Intervention: Other e-cigarette products
Number of subjects: 20
Study 29710165 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise intervention with wearable activity monitor and telephone coaching
Number of subjects: 200
Study 29710165 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no onsite sessions, active exercise, or coaching)
Number of subjects: 200
Study 26497643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 4 months
Number of subjects: 20
Study 26497643 — intervention group
Group type: EXPERIMENTAL
Intervention: Mg-enriched hydroxyapatite (Mg-e HA) grafted into the socket for 12 months
Number of subjects: 20
Study 26497643 — intervention group
Group type: COMPARATOR
Intervention: Comparison of Mg-e HA at 4 months vs 12 months
Number of subjects: 20
Study 24943283 — intervention group
Group type: EXPERIMENTAL
Intervention: Good practice treatment intervention (6 hours contact over 24 weeks, group-based)
Number of subjects: 82
Study 24943283 — intervention group
Group type: COMPARATOR
Intervention: Primary care control group
Number of subjects: 82
Study 22457274 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children
Number of subjects: 0
Study 22457274 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected children with ≥1 malaria episodes
Number of subjects: 0
Study 20921347 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Bereavement Program (FBP)
Number of subjects: 218
Study 20921347 — intervention group
Group type: COMPARATOR
Intervention: Literature Control (LC)
Number of subjects: 218
Study 17726720 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram (8-week trial)
Number of subjects: 84
Study 15940441 — intervention group
Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 56
Study 15940441 — intervention group
Group type: COMPARATOR
Intervention: Intracoronary brachytherapy
Number of subjects: 56
Study 12578870 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP‐1 levels >75th percentile (90th percentile in healthy volunteers)
Number of subjects: 2270
Study 10530439 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial persistence evaluation using serology and PCR analysis
Number of subjects: 37
Study 10530439 — intervention group
Group type: COMPARATOR
Intervention: Control group of patients with end-stage heart disease of known cause
Number of subjects: 37
Study 8688256 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% bupivacaine (group B)
Number of subjects: 60
Study 8688256 — intervention group
Group type: EXPERIMENTAL
Intervention: fentanyl 4 micrograms ml‐1 (group F)
Number of subjects: 60
Study 8688256 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05% bupivacaine combined with fentanyl 2 micrograms ml‐1 (group BF)
Number of subjects: 60
Study 8250364 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B: 20 ml bolus of 0.25% bupivacaine followed by a continuous steady rate infusion (10 ml.h‐1)
Number of subjects: 20
Study 8250364 — intervention group
Group type: COMPARATOR
Intervention: Group C: Normal saline administered in the same way as Group B
Number of subjects: 20
Study 3030861 — intervention group
Group type: EXPERIMENTAL
Intervention: DPTP vaccine (2 doses)
Number of subjects: 320
Study 3030861 — intervention group
Group type: EXPERIMENTAL
Intervention: DPT and IPV (2 doses)
Number of subjects: 320
Study 3030861 — intervention group
Group type: COMPARATOR
Intervention: DPT and OPV (2 doses)
Number of subjects: 320
Study 3030861 — intervention group
Group type: EXPERIMENTAL
Intervention: DPTP vaccine (1 year follow-up)
Number of subjects: 320
Study 31431338 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral ligament (ALL) tunnel aimed at 20° in the coronal plane and 0° in the axial plane
Number of subjects: 32
Study 31431338 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterolateral ligament (ALL) tunnel aimed at 0° coronal and 40° axial angulation
Number of subjects: 32
Study 31431338 — intervention group
Group type: COMPARATOR
Intervention: ACL tunnel drilled by the AMP technique
Number of subjects: 32
Study 31431338 — intervention group
Group type: EXPERIMENTAL
Intervention: Tunnel drilled at 0° in the axial plane
Number of subjects: 32
Study 31431338 — intervention group
Group type: EXPERIMENTAL
Intervention: ALL tunnel orientation adjusted to avoid tunnel conflicts
Number of subjects: 32
Study 29205049 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard protocol (no ramping or pause)
Number of subjects: 320
Study 29205049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramping protocol alone
Number of subjects: 320
Study 29205049 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramping and pause protocols
Number of subjects: 320
Study 29205049 — intervention group
Group type: EXPERIMENTAL
Intervention: Pause protocol alone
Number of subjects: 320
Study 29205049 — intervention group
Group type: COMPARATOR
Intervention: Overall (all groups)
Number of subjects: 320
Study 25367636 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress management intervention combining individual cognitive behavioral therapy (CBT) with a brief workplace intervention (N=57)
Number of subjects: 137
Study 25367636 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=80)
Number of subjects: 137
Study 22844781 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% brimonidine tartrate
Number of subjects: 100
Study 22844781 — intervention group
Group type: COMPARATOR
Intervention: 0.5% timolol maleate
Number of subjects: 100
Study 20151183 — intervention group
Group type: EXPERIMENTAL
Intervention: Syphilis and Men video intervention
Number of subjects: 168
Study 20151183 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 168
Study 17413541 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG) performing glossopharyngeal pistoning (GP) for lung insufflation, 15-30 deep inspiratory efforts, three times per week for 6 weeks.
Number of subjects: 26
Study 17413541 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG) with no intervention.
Number of subjects: 26
Study 17413541 — intervention group
Group type: EXPERIMENTAL
Intervention: Training group (TG) performing GP.
Number of subjects: 26
Study 15309420 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral glucose loading (75 g glucose in 300 mL water)
Number of subjects: 10
Study 15309420 — intervention group
Group type: COMPARATOR
Intervention: Water alone (placebo control)
Number of subjects: 10
Study 12540321 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Number of subjects: 0
Study 12540321 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12540321 — intervention group
Group type: EXPERIMENTAL
Intervention: Antacids and H2 blockers
Number of subjects: 0
Study 10433143 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic appendicectomy
Number of subjects: 99
Study 10433143 — intervention group
Group type: COMPARATOR
Intervention: Open appendicectomy
Number of subjects: 99
Study 10433143 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 99
Study 7659477 — intervention group
Group type: EXPERIMENTAL
Intervention: Lederle vaccine
Number of subjects: 403
Study 7659477 — intervention group
Group type: COMPARATOR
Intervention: MPHBL vaccine
Number of subjects: 403
Study 2679953 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulphadiazine cream (SSD)
Number of subjects: 35
Study 2679953 — intervention group
Group type: COMPARATOR
Intervention: Tulle gras (control dressing)
Number of subjects: 35
Study 175434 — intervention group
Group type: EXPERIMENTAL
Intervention: Metacycline treatment
Number of subjects: 79
Study 175434 — intervention group
Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 79
Study 175434 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycoplasma hominis
Number of subjects: 79
Study 29766292 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g of extra virgin olive oil (EVOO)
Number of subjects: 30
Study 29766292 — intervention group
Group type: COMPARATOR
Intervention: No EVOO
Number of subjects: 30
Study 28618298 — intervention group
Group type: EXPERIMENTAL
Intervention: Online Behavioral Activation treatment
Number of subjects: 42
Study 28618298 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline social functioning
Number of subjects: 42
Study 28618298 — intervention group
Group type: EXPERIMENTAL
Intervention: No stressful life event during therapy
Number of subjects: 42
Study 28618298 — intervention group
Group type: EXPERIMENTAL
Intervention: Completion of more online modules
Number of subjects: 42
Study 28618298 — intervention group
Group type: EXPERIMENTAL
Intervention: Concrete therapist focus
Number of subjects: 42
Study 25051124 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-5 (5 mg.kg‐1)
Number of subjects: 26
Study 25051124 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-3 (3 mg.kg‐1)
Number of subjects: 26
Study 25051124 — intervention group
Group type: EXPERIMENTAL
Intervention: CAF-1 (1 mg.kg‐1)
Number of subjects: 26
Study 25051124 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 26
Study 22772053 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol succinate (up to 190 mg once a day)
Number of subjects: 20
Study 22772053 — intervention group
Group type: EXPERIMENTAL
Intervention: Ivabradine (up to 7.5 mg twice daily)
Number of subjects: 20
Study 21715537 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg/d
Number of subjects: 39
Study 21715537 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 18037672 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (1 mg kg(‐1) bolus and infusion of 5‐10 microg kg(‐1) min(‐1))
Number of subjects: 40
Study 18037672 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Ringer's lactate)
Number of subjects: 40
Study 16431932 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood withdrawal (450 ml)
Number of subjects: 11
Study 16431932 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no blood withdrawal)
Number of subjects: 11
Study 12858325 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day)
Number of subjects: 184
Study 12858325 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine (20 mg/day)
Number of subjects: 184
Study 10881828 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg/kg intravenously)
Number of subjects: 29
Study 9196462 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone-setting
Number of subjects: 114
Study 9196462 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 114
Study 9196462 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy
Number of subjects: 114
Study 8418243 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clodronate 1,600 mg/d
Number of subjects: 173
Study 8418243 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 2868413 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal gonadotropin-releasing hormone (1.2 mg per day for 28 days)
Number of subjects: 33
Study 29535135 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed-loop insulin delivery
Number of subjects: 16
Study 29535135 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP) insulin delivery
Number of subjects: 16
Study 29535135 — intervention group
Group type: COMPARATOR
Intervention: SAP insulin delivery
Number of subjects: 16
Study 27721093 — intervention group
Group type: EXPERIMENTAL
Intervention: Posterior approach
Number of subjects: 47
Study 27721093 — intervention group
Group type: COMPARATOR
Intervention: Lateral approach
Number of subjects: 47
Study 25037033 — intervention group
Group type: EXPERIMENTAL
Intervention: Heptavalent vaccine
Number of subjects: 480
Study 25037033 — intervention group
Group type: COMPARATOR
Intervention: Hexavalent and monovalent MenC control vaccines
Number of subjects: 480
Study 22311000 — intervention group
Group type: EXPERIMENTAL
Intervention: Peel-away sheath
Number of subjects: 201
Study 22311000 — intervention group
Group type: COMPARATOR
Intervention: No peel-away sheath
Number of subjects: 201
Study 22311000 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall
Number of subjects: 201
Study 20299307 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin (500 mg daily for 4 days with a gap of 10 days, total 24 courses for 48 weeks)
Number of subjects: 50
Study 20299307 — intervention group
Group type: COMPARATOR
Intervention: Vitamin C tablet (non-chewable, same dosage schedule as azithromycin)
Number of subjects: 50
Study 18716298 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (24 mg/m², max 40 mg, subcutaneously every other week for 16 weeks)
Number of subjects: 171
Study 18716298 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 18716298 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 171
Study 16156905 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of suction drains during surgery
Number of subjects: 8
Study 16156905 — intervention group
Group type: COMPARATOR
Intervention: No use of suction drains during surgery
Number of subjects: 8
Study 12407608 — intervention group
Group type: EXPERIMENTAL
Intervention: Prepuncture ultrasound guidance
Number of subjects: 240
Study 12407608 — intervention group
Group type: COMPARATOR
Intervention: Landmark-guided puncture
Number of subjects: 240
Study 10504107 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute time-frame hospital-based video intervention
Number of subjects: 0
Study 10504107 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study 8756373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 0.6 mg three times daily
Number of subjects: 54
Study 8756373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 1 mg twice daily
Number of subjects: 54
Study 8756373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride 2 mg twice daily
Number of subjects: 54
Study 8756373 — intervention group
Group type: EXPERIMENTAL
Intervention: Fadrozole hydrochloride (all doses combined)
Number of subjects: 54
Study 1743819 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (NI) chewing gum
Number of subjects: 496
Study 1743819 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver acetate (SA) chewing gum
Number of subjects: 496
Study 1743819 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL) chewing gum
Number of subjects: 496
Study 7234694 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (4.0 g/day)
Number of subjects: 8
Study 7234694 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30721159 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐adapted CM protocol (0.4 g I/kg dosing factor, TIL adapted to weight)
Number of subjects: 199
Study 30721159 — intervention group
Group type: COMPARATOR
Intervention: Fixed CM dose (33 g I, 110 mL volume)
Number of subjects: 199
Study 30721159 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight‐adapted CM protocol
Number of subjects: 199
Study 30721159 — intervention group
Group type: COMPARATOR
Intervention: Fixed CM volume
Number of subjects: 199
Study 30214029 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting program (Nurse-Family Partnership)
Number of subjects: 512
Study 24567912 — intervention group
Group type: EXPERIMENTAL
Intervention: Coherence analysis
Number of subjects: 308
Study 24567912 — intervention group
Group type: EXPERIMENTAL
Intervention: Graph theoretical network analyses
Number of subjects: 308
Study 24567912 — intervention group
Group type: EXPERIMENTAL
Intervention: Modularity analysis
Number of subjects: 308
Study 22985437 — intervention group
Group type: COMPARATOR
Intervention: Normal-PI (NPI: 1.0 g/kg/day)
Number of subjects: 28
Study 22985437 — intervention group
Group type: EXPERIMENTAL
Intervention: High-PI (HPI: 1.2 g/kg/day)
Number of subjects: 28
Study 19007842 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC)
Number of subjects: 52
Study 19007842 — intervention group
Group type: COMPARATOR
Intervention: Carbamazepine (CBZ)
Number of subjects: 52
Study 17719932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen (20 to 30 mg/kg/twice daily, adjusted to a peak serum concentration of 50 to 100 mug/mL)
Number of subjects: 142
Study 17719932 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ibuprofen
Number of subjects: 142
Study 17719932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 142
Study 15513354 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-H. pylori treatment
Number of subjects: 142
Study 15513354 — intervention group
Group type: COMPARATOR
Intervention: Control (subjects without dyspepsia)
Number of subjects: 142
Study 11133596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 49
Study 11133596 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil (50 microg)
Number of subjects: 49
Study 11133596 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of intrathecal morphine and sufentanil
Number of subjects: 49
Study 11133596 — intervention group
Group type: COMPARATOR
Intervention: IV morphine (patient-controlled analgesia)
Number of subjects: 49
Study 9036884 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO) treatment at two atmospheres of pressure for 90 minutes twice a day for a minimum of 10 treatments
Number of subjects: 125
Study 9036884 — intervention group
Group type: COMPARATOR
Intervention: Control group treated similarly but without HBO
Number of subjects: 125
Study 7944639 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg of hyaluronan (Hyalgan) in 2 ml of buffered saline, administered weekly for 5 weeks
Number of subjects: 91
Study 7944639 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert vehicle)
Number of subjects: 91
Study 7944639 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyalgan (treatment group)
Number of subjects: 91
Study 2979277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine administration at 18.00 hours
Number of subjects: 12
Study 2979277 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine administration at 22.00 hours
Number of subjects: 12
Study 2979277 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine administration with food
Number of subjects: 12
Study 2979277 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine administration without food
Number of subjects: 12
Study 2979277 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine administration at both times
Number of subjects: 12
Study 31564620 — intervention group
Group type: EXPERIMENTAL
Intervention: External cooling and vibration devices
Number of subjects: 60
Study 31564620 — intervention group
Group type: COMPARATOR
Intervention: Local mandibular anesthesia without any other procedure
Number of subjects: 60
Study 30453344 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide co-administration
Number of subjects: 9
Study 27404010 — intervention group
Group type: COMPARATOR
Intervention: US $10 compensation
Number of subjects: 4000
Study 27404010 — intervention group
Group type: COMPARATOR
Intervention: Challenge with 'Are you tough enough?'
Number of subjects: 4000
Study 27404010 — intervention group
Group type: COMPARATOR
Intervention: Partner preference information
Number of subjects: 4000
Study 27404010 — intervention group
Group type: COMPARATOR
Intervention: VMMC nurse hotline
Number of subjects: 4000
Study 24043395 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate exercise (MOD; 300 kcal/day)
Number of subjects: 61
Study 24043395 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose exercise (HIGH; 600 kcal/day)
Number of subjects: 61
Study 24043395 — intervention group
Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 61
Study 22716224 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin 75 mg (oral capsule)
Number of subjects: 15
Study 20557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) by the same examiner
Number of subjects: 200
Study 20557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Stratus optical coherence tomography (OCT) by different examiners
Number of subjects: 200
Study 20557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Macular thickness program
Number of subjects: 200
Study 20557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast macular thickness program
Number of subjects: 200
Study 20557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Threshold algorithm line failures
Number of subjects: 200
Study 20557937 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum retinal thickness (MRT)
Number of subjects: 200